OslerW.The Principles and Practice of Medicine. D. Appleton and Co.: New York, NY, USA; 1898.
2.
KahalyGJ, Gottwald-HostalekU. Use of levothyroxine in the management of hypothyroidism: A historical perspective. Front Endocrinol (Lausanne), 2022; 13:1054983; doi: 10.3389/fendo.2022.1054983.
3.
ClinCalc DrugStats Database. Available from: https://clincalc.com>drugstats [Last accessed: May 1, 2023].
4.
StedmanM, TaylorP, PremawardhanaL, et al.Liothyronine and levothyroxine prescribing in England: A comprehensive survey and evaluation. Int J Clin Pract, 2021; 75(9):e14228; doi: 10.1111/ijcp.14228.
5.
SaravananP, ChauWF, RobertsN, et al.Psychological well-being in patients on “adequate” doses of l-thyroxine: Results of a large, controlled community-based questionnaire study. Clin Endocrinol, 2002; 57(5):577–585.
6.
PetersonSJ, CappolaAR, CastroMR, et al.An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid, 2018; 28(6):707–721; doi: 10.1089/thy.2017.0681.
7.
PerrosP, NagyEV, PapiniE, et al.Hypothyroidism and somatization: Results from E-mode patient self-assessment of thyroid therapy, a cross-sectional, international online patient survey. Thyroid, 2023; 33(8):927–939; doi: 10.1089/thy.2022.0641.
8.
MehuysE, LapauwB, T'SjoenG, et al.Investigating levothyroxine use and its association with thyroid health in patients with hypothyroidism: A community pharmacy study. Thyroid, 2023; 33(8):918–928; doi: 10.1089/thy.2023.0066.
9.
RodondiN, den ElzenWP, BauerDC, et al.Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 2010; 304(12):1365–1374; doi: 10.1001/jama.2010.1361.
ParleJV, FranklynJA, CrossKW, et al.Thyroxine prescription in the community: Serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J General Pract, 1993; 43(368):107–109.
12.
AokiY, BelinRM, ClicknerR, et al.Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999–2002). Thyroid, 2007; 17(12):1211–1223; doi: 10.1089/thy.2006.0235.
13.
CarleA, FaberJ, SteffensenR, et al.Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3 + L-T4 combination treatment—Data using a blind, randomized, clinical study. Eur Thyroid J, 2017; 6(3):143–151; doi: 10.1159/000469709.
14.
JonklaasJ, BiancoAC, CappolaAR, et al.Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: A consensus document. Thyroid, 2021; 31(2):156–182; doi: 10.1089/thy.2020.0720.
15.
StottDJ, RodondiN, KearneyPM, et al.Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med, 2017; 376(26):2534–2544; doi: 10.1056/NEJMoa1603825.
16.
SamuelsMH, KolobovaI, NiederhausenM, et al.Effects of altering levothyroxine (L-T4) doses on quality of life, mood, and cognition in L-T4 treated subjects. J Clin Endocrinol Metab, 2018; 103(5):1997–2008; doi: 10.1210/jc.2017-02668.
17.
WerneckFZ, CoelhoEF, AlmasSP, et al.Exercise training improves quality of life in women with subclinical hypothyroidism: A randomized clinical trial. Arch Endocrinol Metab, 2018; 62(5):530–536; doi: 10.20945/2359-3997000000073.
18.
RezaeiS, AbediP, MaraghiE, et al.The effectiveness of cognitive-behavioral therapy on quality of life in women with hypothyroidism in the reproductive age: A randomized controlled trial. Thyroid Res, 2020; 13:6; doi: 10.1186/s13044-020-00080-z.
